Literature DB >> 4030540

Reduced ampicillin bioavailability following oral coadministration with chloroquine.

H M Ali.   

Abstract

Ampicillin bioavailability was examined in seven healthy adult male volunteers after oral coadministration with chloroquine using the urinary excretion method. Ampicillin (500 mg, capsules) and chloroquine phosphate (250 mg, tablets) were administered in single doses of 1.0 g each. Each subject received, on two different occasions, ampicillin alone and ampicillin together chloroquine. Urine was collected hourly for 8.0 h. Ampicillin urinary levels were measured chemically. The mean % dose excreted, maximum peak of excretion and the time of that peak after the administration of ampicillin alone were: 29 +/- 4.1%, 1.73 +/- 0.27 mg/min and 1.75 +/- 0.164 h, respectively. The corresponding values after coadministration of ampicillin with chloroquine were: 19 +/- 2.9%, 1.25 +/- 0.17 mg/min and 1.82 +/- 0.210 h. The results indicate a significant reduction (P less than 0.005) in ampicillin bioavailability following oral coadministration with chloroquine. The reduction of ampicillin bioavailability produced by chloroquine might be attributed to slowing of gastric emptying and enhancement of gut motility induced by the chloroquine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4030540     DOI: 10.1093/jac/15.6.781

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda.

Authors:  C Obua; M Ntale; M S Lundblad; M Mahindi; L L Gustafsson; J W Ogwal-Okeng; W W Anokbonggo; U Hellgren
Journal:  Afr Health Sci       Date:  2006-06       Impact factor: 0.927

Review 2.  A Quantitative Review and Meta-models of the Variability and Factors Affecting Oral Drug Absorption-Part II: Gastrointestinal Transit Time.

Authors:  Ahmad Y Abuhelwa; David J R Foster; Richard N Upton
Journal:  AAPS J       Date:  2016-07-20       Impact factor: 4.009

Review 3.  Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.

Authors:  Haleh Rezaee; Fariba Pourkarim; Samira Pourtaghi-Anvarian; Taher Entezari-Maleki; Touraj Asvadi-Kermani; Masoud Nouri-Vaskeh
Journal:  Pharmacol Res Perspect       Date:  2021-02

Review 4.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

5.  Significant Pharmacokinetic Interactions Between Quinine and Ampicillin-Cloxacillin Combination.

Authors:  Olubunmi B Falade; Adeyinka G Falusi; Ajibola A Olaniyi; Chizoba Ezeasor; David A Kwasi; Chinedum P Babalola
Journal:  Drugs R D       Date:  2016-06

6.  Quinoline Antimalarials Increase the Antibacterial Activity of Ampicillin.

Authors:  Olajumoke A Olateju; Chinedum P Babalola; Olujide O Olubiyi; Olayinka A Kotila; David A Kwasi; Anderson O Oaikhena; Iruka N Okeke
Journal:  Front Microbiol       Date:  2021-06-02       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.